Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals (Nasdaq:XFOR) granted inducement stock options to new employees under its 2019 Inducement Equity Incentive Plan, effective May 29, 2026. The awards cover 160,000 shares at an exercise price of $4.31 per share, with a ten-year term and four-year vesting schedule.
X4 Pharmaceuticals (Nasdaq:XFOR) announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 3:45 p.m. ET. A live and archived webcast of the presentation will be available via the Investors section of the company’s website.
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q1 2026 results and a corporate update on May 6, 2026. Key items: EU marketing authorization for XOLREMDI (mavorixafor) for WHIM syndrome, continued enrollment progress in the global 4WARD Phase 3 chronic neutropenia trial, and a $233.7M cash balance providing runway through 2028. The Norgine license could yield up to €226M in milestones plus escalating royalties; Q1 revenue was $2.7M versus $28.8M prior year, and net loss was $(20.2)M.
X4 Pharmaceuticals (Nasdaq: XFOR) announced European Commission marketing authorization for XOLREMDI (mavorixafor) to treat WHIM syndrome in patients 12 years and older, granted under exceptional circumstances. The authorization follows a positive CHMP opinion and is supported by the pivotal Phase 3 4WHIM trial in 31 patients.
European commercialization will be led by partner Norgine under a 2025 license and supply agreement with up to €226 million in contingent payments plus escalating royalties; X4 will manufacture and supply the medicine.
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective March 31, 2026, granting options to purchase an aggregate of 32,000 shares under its 2019 Inducement Equity Incentive Plan.
The options carry a 10-year term, an exercise price of $4.13 (closing price on March 31, 2026) and a four-year vesting schedule (25% after 12 months, then monthly over 36 months).
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q4 and full‑year 2025 results and a corporate update on March 17, 2026. Key items: 4WARD Phase 3 enrollment on track to complete in Q3 2026, a positive CHMP opinion for mavorixafor in WHIM syndrome, and a $253.0M cash position that management says funds operations through 2028.
Financials: 2025 product sales $6.5M, license revenue $28.6M, operating loss $86.9M, and net loss $79.2M for the year ended December 31, 2025.
X4 Pharmaceuticals (NASDAQ: XFOR) said management will join a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami. A live and archived webcast will be available on the company’s Investors site under Events and Presentations.
X4 Pharmaceuticals (Nasdaq: XFOR) announced inducement equity awards effective February 27, 2026, granting options to purchase an aggregate of 24,000 shares to new employees under its 2019 Inducement Equity Incentive Plan.
The options have a 10-year term, an exercise price of $3.44 (closing price on February 27, 2026) and vest 25% after 12 months, then monthly over 36 months, subject to continued employment and plan terms; grants were approved by the compensation committee per Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (Nasdaq: XFOR) announced the EMA CHMP has issued a positive opinion recommending marketing authorization under exceptional circumstances for mavorixafor (XOLREMDI) to treat WHIM syndrome in the EU. The European Commission is expected to issue a final decision in Q2 2026.
CHMP support is based on the Phase 3 4WHIM trial showing statistically significant increases in ANC and ALC thresholds, ~40% reduction in total infection score, and a 60% reduction in annualized infection rate versus placebo. X4 has a commercialization license with Norgine and may receive up to €226 million plus escalating royalties.
X4 Pharmaceuticals (Nasdaq: XFOR) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11–12, 2026 in New York.
The company will hold a fireside chat on February 12 at 12:30 p.m. ET, offer one-on-one investor meetings, and provide a webcast and 30-day replay on its Investors Events and Presentations page.